

**AMERICAN VIETNAMESE
BIOTECH INC**

**SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness**

Number: 39/2026/CV - AMV

Ho Chi Minh City, July 30, 2026

*Subject: Disclosure of Financial Statements for
Q2/2026 and Explanation of profit discrepancies*

**Dear: - STATE SECURITIES COMMISSION;
- HANOI STOCK EXCHANGE.**

Company Name: **AMERICAN VIETNAMESE BIOTECH INC**

Stock ticker: **AMV**

Head office address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai Street, Tan My Ward,
Ho Chi Minh City, Vietnam

Phone: Fax:

Information released by: **Dang Nhi Nuong**

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai Street, Tan My Ward, Ho Chi
Minh City, Vietnam.

Telephone (mobile, office, home):

Type of information to be released: ☐ 24-hour ☐ irregular ☐ information as requested ☒
periodically

Content of published information (*):

In accordance with Circular No. 96/2020/TT-BTC dated November 16, 2020, of the Ministry of
Finance, American Vietnamese Biotech Inc hereby reports to the Committee and the Department on
the disclosure of the Financial Report for the second quarter of 2026 as follows:

I. Separate financial statements

1. Explanation of the change in after-tax profit in the Statement of Income for the reporting period
of 10% or more compared to the same period of the previous year, shifting from profit in the
same period of the previous year to loss in this period, is as follows:

- Business results for the second quarter of 2025
 - + Revenue: 2,986,430,973 VND
 - + Cost of goods sold: 3,752,467,590 VND
 - + Net profit after tax: (23,531,697,967) VND
- Business results for the second quarter of 2026
 - + Revenue: 7,847,536,993 VND
 - + Cost of goods sold: 6,672,767,732 VND
 - + Net profit after tax: (10,248,491,212) VND

2. Explanation of the reasons

The after-tax profit on the parent company's Q2 2026 financial statement is VND
10,248,491,212. The main reason is the increase in revenue and the decrease in provisions for
financial investments compared to the same period last year.



II. Consolidated financial statements

1. Explanation of the change in after-tax profit in the Statement of Income for the reporting period of 10% or more compared to the same period of the previous year, shifting from profit in the same period of the previous year to loss in this period, is as follows:

- Business results for the second quarter of 2025
 - + Revenue: 38,298,619,222 VND
 - + Cost of goods sold: 35,529,269,264 VND
 - + Net profit after tax: (37,629,276,939) VND
- Business results for the second quarter of 2026
 - + Revenue: 37,369,431,491 VND
 - + Cost of goods sold: 35,263,557,382 VND
 - + Net profit after tax: (27,395,735,464) VND

2. Explanation of the reasons

The after-tax profit on the Company's Consolidated Financial Statements for the second quarter of 2026 was VND 27,395,735,464. The main reason is the reduction in provisions for financial investments compared to the same period last year.

III. The above information was posted on our company's website on July 30, 2026 at the following address:

<https://amvibiotech.com/category/bao-cao-tai-chinh/>

American Vietnamese Biotech Inc commits that the information provided above is truthful and accurate.

Thank you very much!

Recipient:

- As above.
- Save VP.

AMERICAN VIETNAMESE BIOTECH INC



GIÁM ĐỐC

Dặng Nhị Nương

